Diamond Hill Capital Management Inc. Sells 9,310 Shares of uniQure (NASDAQ:QURE)

Diamond Hill Capital Management Inc. trimmed its stake in shares of uniQure (NASDAQ:QURE) by 12.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,320 shares of the biotechnology company’s stock after selling 9,310 shares during the quarter. Diamond Hill Capital Management Inc. owned about 0.14% of uniQure worth $1,189,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Monaco Asset Management SAM bought a new position in uniQure during the fourth quarter worth $2,414,000. Raymond James Financial Inc. acquired a new position in shares of uniQure in the fourth quarter valued at about $1,951,000. Oppenheimer & Co. Inc. acquired a new position in shares of uniQure in the fourth quarter valued at about $320,000. Palumbo Wealth Management LLC acquired a new position in shares of uniQure in the fourth quarter valued at about $437,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 969 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on QURE shares. Mizuho upped their price target on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 19th. Wells Fargo & Company decreased their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Friday, February 28th. Guggenheim restated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of uniQure in a research note on Tuesday, March 4th. Finally, Raymond James raised shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $20.00 to $52.00 in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $38.89.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 6,717 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the completion of the transaction, the chief executive officer now owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. This represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christian Klemt sold 10,438 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the transaction, the chief financial officer now directly owns 217,730 shares of the company’s stock, valued at $2,240,441.70. This trade represents a 4.57 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is currently owned by insiders.

uniQure Stock Up 3.0 %

QURE stock opened at $14.20 on Friday. The stock has a market capitalization of $767.89 million, a P/E ratio of -2.86 and a beta of 0.36. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $19.18. The firm has a 50-day moving average price of $14.02 and a 200-day moving average price of $10.19.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.